Halozyme Therapeutics Inc (HALO)

[Fred Kadiddlehopper]

That's a great summary and calls into question the HALO guidance of $1 billion in royalties by 2027.
The one thing I'd be able to add is that you are on to something regarding how darzalex was a perfect alignment of interests. The fact is that many IV drugs are not necessarily going to switch to subcu. For example, the Lilly MAB for Covid-19 only takes an hour or less, so will there be a strong market incentive to adopt a subcu version? I doubt it. So the market for Enhanz might not be as great as once thought.
Add to that the alternative subcu formulations that appear to be quietly percolating and we have a worrisome stage set while we await the next shoe to drop in this long saga.